Divi’s Laboratories Ltd. reported a 63.6% YoY increase in consolidated profit after tax to Rs.1,127 crore for Q2 FY27, compared with Rs.689 crore in the corresponding quarter last year. Revenue from operations rose 35.4% to Rs.3,676 crore from Rs.2,715 crore, reflecting stronger business performance during the quarter.
The company’s total income increased to Rs.3,770 crore from Rs.2,860 crore a year earlier. Divi’s Laboratories operates in the pharmaceutical industry, manufacturing active pharmaceutical ingredients, intermediates and custom synthesis products for global customers.
The strong quarterly growth places the company among the notable performers in the pharmaceutical sector during the current earnings season. Investors will continue to monitor demand from international markets, product mix and operating margins in the coming quarters.
Source: The Economic Times – Divi’s Laboratories Q2 Results.
